Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q2 2026
Amphastar Pharmaceuticals (AMPH) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Amphastar Pharmaceuticals (AMPH) reported revenue of $184M for the second quarter 2026 (Q2 2026), +5% from a year earlier and +7% from the quarter before. Operating margin was 21.6%, net earnings $30.3M (16.5% of revenue).
Amphastar Pharmaceuticals, Q2 2026: revenue $184M (+5% year over year), operating margin 21.6%, net earnings $30.3M, operating cash flow $51.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $184M | +7% | +5% |
| Gross profit | $93.5M | +33% | +8% |
| Operating profit | $39.7M | +191% | -6% |
| Net earnings | $30.3M | +373% | -2% |
| Operating cash flow | $51.3M | +7% | +44% |
| Free cash flow | $42.7M | +11% | +71% |
What changed
Revenue was $183.9M in Q2 2026, up 5% year over year and up 7% from the previous quarter.
Gross margin was 50.8%, up 1.2 points from Q2 2025. Operating profit was $39.7M, a 21.6% margin (down 2.6 points year over year). Operating profit fell $2.5M even though revenue rose $9.5M versus Q2 2025, so costs grew faster than sales. Operating expenses grew 21% against revenue growth of 5%. The fastest-growing cost line was General & admin (+30%). Net earnings were $30.3M, down 2% year over year. The effective tax rate was 21.3%.
Operating cash flow was $51.3M (up 44% year over year), 169% of net earnings. Non-cash charges added back $14.3M of depreciation and amortization and $7.1M of share-based compensation. Capital expenditures of $8.6M left free cash flow of $42.7M.
Questions
What was Amphastar Pharmaceuticals' revenue in the second quarter 2026?
Amphastar Pharmaceuticals (AMPH) reported revenue of $184M for the second quarter 2026 (Q2 2026), +5% from a year earlier and +7% from the quarter before.
Was Amphastar Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $39.7M (21.6% of revenue) and net earnings $30.3M.